TABLE 1.

Overview of included studies.

Study ID; location	Study design; number of patients	Study population	Treatment formulation evaluated	Treatment period
DEB‐96‐TRI‐01 first phase; South Africa	Phase III, 19 centres, open‐label, randomised, controlled, 2‐arm; N = 335	Advanced prostate cancer	Triptorelin pamoate 3.75 mg IM every 4 weeks Triptorelin 11.25 mg IM every 12 weeks	9 months (252 days)
DEB‐96‐TRI‐01 second phase; South Africa	Phase III, 29 centres, open‐label, randomised, controlled, 2‐arm; N = 277	Advanced prostate cancer	Triptorelin pamoate 3.75 mg IM every 4 weeks	9 months (252 days)
DEB‐TRI6M‐301; South Africa NCT00751790	Phase III, 13 centres, open‐label, 1‐arm; N = 120	Advanced prostate cancer	Triptorelin pamoate 22.5 mg IM every 24 weeks	12 months (336 days)

Abbreviation: IM, intramuscular.